Kenneth Cusi

List of Publications by Year
in descending order

154	27,662	13854 67	9090 144
papers	citations	h-index	g-index

157	157	157	22706
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67, 328-357.	3.6	4,738
2	The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012, 55, 2005-2023.	3.6	2,935
3	A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. New England Journal of Medicine, 2006, 355, 2297-2307.	13.9	1,584
4	The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 2012, 142, 1592-1609.	0.6	1,486
5	Insulin resistance differentially affects the PI 3-kinaseâ€“ and MAP kinaseâ€“mediated signaling in human muscle. Journal of Clinical Investigation, 2000, 105, 311-320.	3.9	953
6	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine, 2021, 384, 1113-1124.	13.9	833
7	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus. Annals of Internal Medicine, 2016, 165, 305.	2.0	732
8	Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications. Gastroenterology, 2012, 142, 711-725.e6.	0.6	711
9	Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2784-2791.	1.8	629
10	Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes and Endocrinology,the, 2019, 7, 313-324.	5.5	566
11	Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects. Gastroenterology, 2007, 133, 496-506.	0.6	500
12	A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes. Diabetes, 2003, 52, 2461-2474.	0.3	447
13	High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2231-2238.	1.8	404
14	Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 4059-4067.	1.8	349
15	Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology, 2012, 55, 1389-1397.	3.6	348
16	Dose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling. Diabetes, 2005, 54, 1640-1648.	0.3	333
17	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	8.2	330
18	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. Endocrine Practice, 2022, 28, 528-562.	1.1	323

#	Article	IF	Citations
19	Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 70, 711-724.	3.6	305
20	Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 4059-4067.	1.8	285
21	Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Diabetes Care, 2017, 40, 419-430.	4.3	256
22	From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Reports, 2019, 1, 312-328.	2.6	251
23	The Role of Adipose Tissue and Lipotoxicity in the Pathogenesis of Type 2 Diabetes. Current Diabetes Reports, 2010, 10, 306-315.	1.7	239
24	A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes and Endocrinology,the, 2022, 10, 284-296.	5.5	232
25	Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology, 2009, 50, 1087-1093.	3.6	231
26	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2021, 161, 1657-1669.	0.6	229
27	Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. Trends in Endocrinology and Metabolism, 2017, 28, 250-260.	3.1	228
28	Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2014, 60, 167-174.	1.8	223
29	Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD). Diabetes Care, 2012, 35, 873-878.	4.3	214
30	Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care, 2019, 42, 1481-1488.	4.3	202
31	Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis. Clinics in Liver Disease, 2009, 13, 545-563.	1.0	192
32	Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology, 2017, 65, 1132-1144.	3.6	191
33	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 24-39.	8.2	174
34	Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care, 2021, 44, 399-406.	4.3	173
35	Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver International, 2015, 35, 2139-2146.	1.9	169
36	Saroglitazar, a PPARâ€Î±/Î³ Agonist, for Treatment of NAFLD: A Randomized Controlled Doubleâ€Blind Phase 2 Trial. Hepatology, 2021, 74, 1809-1824.	3.6	163

#	Article	IF	Citations
37	The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology, 2015, 61, 153-160.	3.6	156
38	Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 393-406.	5.5	155
39	Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clinical Gastroenterology and Hepatology, 2018, 16, 558-566.e2.	2.4	154
40	Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 141-149.	1.2	150
41	Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 829-836.	1.8	143
42	Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. Journal of Hepatology, 2020, 72, 613-626.	1.8	143
43	Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches. Drugs, 2013, 73, 1-14.	4.9	139
44	Nonâ€alcoholic fatty liver disease (<scp>NAFLD</scp>) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1630-1634.	2.2	137
45	Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology, 2014, 59, 2178-2187.	3.6	129
46	Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 644-652.	1.8	127
47	Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E484-E494.	1.8	126
48	Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovascular Diabetology, 2010, 9, 9.	2.7	120
49	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 812-821.	2.2	117
50	Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes. Diabetes Care, 2020, 43, 290-297.	4.3	113
51	Normalization of Plasma Glucose Concentration by Insulin Therapy Improves Insulin-Stimulated Glycogen Synthesis in Type 2 Diabetes. Diabetes, 2002, 51, 462-468.	0.3	109
52	New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Annals of Medicine, 2009, 41, 265-278.	1.5	108
53	Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 632-638.	4.3	108
54	Nonalcoholic Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America, 2016, 45, 765-781.	1.2	107

#	Article	IF	Citations
55	Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia, 2016, 59, 1112-1120.	2.9	102
56	The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus. Current Diabetes Reports, 2013, 13, 329-341.	1.7	101
57	Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. Journal of Hepatology, 2015, 62, 405-411.	1.8	98
58	Pioglitazone in the treatment of NASH: the role of adiponectin. Alimentary Pharmacology and Therapeutics, 2010, 32, 769-775.	1.9	97
59	Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E1775-E1781.	1.8	89
60	Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease. American Journal of Physiology - Endocrinology and Metabolism, 2015, 309, E311-E319.	1.8	88
61	Pharmacological management of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2016, 65, 1183-1195.	1.5	86
62	The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 29-38.	1.8	82
63	Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology, 2011, 54, 837-845.	3.6	74
64	Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2007, 47, 565-570.	1.8	73
65	Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Annals of Hepatology, 2020, 19, 674-690.	0.6	72
66	Defining comprehensive models of care for NAFLD. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 717-729.	8.2	72
67	Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obesity, 2021, 29, 1950-1960.	1.5	70
68	Safety and Efficacy of Normalizing Fasting Glucose With Bedtime NPH Insulin Alone in NIDDM. Diabetes Care, 1995, 18, 843-851.	4.3	68
69	Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3327-3336.	1.8	68
70	Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2950-2961.	1.8	66
71	Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the <scp>AWARD</scp> programme. Diabetic Medicine, 2018, 35, 1434-1439.	1.2	59
72	Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. Journal of Investigative Medicine, 2019, 67, 303-311.	0.7	59

#	Article	IF	Citations
73	Preparing for the NASH Epidemic: A Call to Action. Gastroenterology, 2021, 161, 1030-1042.e8.	0.6	58
74	Prediabetes. Endocrinology and Metabolism Clinics of North America, 2016, 45, 751-764.	1.2	55
75	PPARâ€Î³â€induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver International, 2021, 41, 2659-2670.	1.9	51
76	Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E163-E173.	1.8	50
77	Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo. Metabolism: Clinical and Experimental, 2011, 60, 1090-1099.	1.5	49
78	Glucagon like Peptide-1 Receptor Agonists for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: A Novel Therapeutic Option. Journal of Investigative Medicine, 2018, 66, 7-10.	0.7	49
79	Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes. Diabetes Care, 2020, 43, 275-279.	4.3	49
80	Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. Clinical Diabetes and Endocrinology, 2016, 2, 9.	1.3	45
81	Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?. American Journal of Medicine, 2020, 133, 536-543.	0.6	43
82	Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. Journal of Hepatology, 2020, 72, 401-410.	1.8	40
83	Use of a metabolomic approach to nonâ€invasively diagnose nonâ€alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2018, 20, 1702-1709.	2.2	39
84	Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Current Diabetes Reports, 2020, 20, 59.	1.7	39
85	Improved experimental data processing for UHPLCâ€“HRMS/MS lipidomics applied to nonalcoholic fatty liver disease. Metabolomics, 2017, 13, 1.	1.4	38
86	Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Contemporary Clinical Trials, 2017, 61, 33-38.	0.8	38
87	Unmet Needs in Hispanic/Latino Patients with Type 2 Diabetes Mellitus. American Journal of Medicine, 2011, 124, S2-S9.	0.6	37
88	Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care, 2018, 41, 187-192.	4.3	37
89	Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes. Diabetes Care, 2019, 42, 1348-1351.	4.3	37
90	Incretinâ€Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. Hepatology, 2019, 69, 2318-2322.	3.6	37

#	Article	IF	Citations
91	A diabetologistâ€™s perspective of nonâ€alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. Liver International, 2020, 40, 82-88.	1.9	36
92	Effect of all-extremity high-intensity interval training vs. moderate-intensity continuous training on aerobic fitness in middle-aged and older adults with type 2 diabetes: A randomized controlled trial. Experimental Gerontology, 2019, 116, 46-53.	1.2	31
93	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology, 2022, 76, 1121-1134.	3.6	31
94	An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Therapeutic Advances in Endocrinology and Metabolism, 2011, 2, 211-225.	1.4	30
95	Preparing for the NASH Epidemic: A Call to Action. Diabetes Care, 2021, 44, 2162-2172.	4.3	30
96	Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 50-58.	2.2	29
97	Concentrationâ€dependent response to pioglitazone in nonalcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2017, 46, 56-61.	1.9	28
98	Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clinical Pharmacology and Therapeutics, 2006, 80, 105-114.	2.3	26
99	Plasma Thyroid Hormone Concentration is Associated with Hepatic Triglyceride Content in Patients with Type 2 Diabetes. Journal of Investigative Medicine, 2016, 64, 63-68.	0.7	26
100	Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36â€month clinical trial. Journal of Diabetes, 2019, 11, 223-231.	0.8	26
101	Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. The Lancet Gastroenterology and Hepatology, 2021, 6, 889-902.	3.7	26
102	Nonalcoholic steatohepatitis in nonobese patients: Not so different after all. Hepatology, 2017, 65, 4-7.	3.6	25
103	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. Contemporary Clinical Trials, 2020, 97, 106174.	0.8	25
104	Preparing for the NASH epidemic: A call to action. Metabolism: Clinical and Experimental, 2021, 122, 154822.	1.5	25
105	Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. Journal of Endocrinology, 2019, 241, 293-305.	1.2	25
106	The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease. Clinical Lipidology, 2012, 7, 471-481.	0.4	23
107	A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. Frontiers in Pharmacology, 2018, 9, 752.	1.6	23
108	Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus. Current Diabetes Reports, 2009, 9, 200-207.	1.7	22

#	Article	IF	Citations
109	Chronic Lowâ€Dose Lipid Infusion in Healthy Patients Induces Markers of Endothelial Activation Independent of Its Metabolic Effects. Journal of the Cardiometabolic Syndrome, 2008, 3, 141-146.	1.7	21
110	Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGETâ€NASH Study. Hepatology Communications, 2021, 5, 938-946.	2.0	21
111	Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care, 2021, 44, 1344-1352.	4.3	21
112	Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Current Hepatology Reports, 2014, 13, 159-170.	0.4	20
113	Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy. Journal of Investigative Medicine, 2020, 68, 743-747.	0.7	13
114	A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 969, 219-223.	1.2	12
115	Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study. European Journal of Endocrinology, 2021, 184, 587-596.	1.9	12
116	Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study. Cell Reports Medicine, 2021, 2, 100474.	3.3	12
117	The relationship between hepatitis C virus infection and diabetes: Time for a divorce?. Hepatology, 2014, 60, 1121-1123.	3.6	11
118	Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes. PLoS ONE, 2021, 16, e0251449.	1.1	11
119	Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes. Obesity, 2022, 30, 1231-1238.	1.5	11
120	Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus. Gut, 2018, 67, 1371-1371.	6.1	10
121	Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart. Current Opinion in Lipidology, 2020, 31, 364-366.	1.2	10
122	Liver biopsy in the real worldâ€”reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Alimentary Pharmacology and Therapeutics, 2021, 54, 1472-1480.	1.9	10
123	Neurocognitive Deficits in a Cohort With Class 2 and Class 3 Obesity: Contributions of Type 2 Diabetes and Other Comorbidities. Obesity, 2019, 27, 1099-1106.	1.5	8
124	Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis. PLoS ONE, 2019, 14, e0219855.	1.1	7
125	Preparing for the NASH epidemic: A call to action. Obesity, 2021, 29, 1401-1412.	1.5	7
126	Editorial: diabetes, obesity and clinical inertiaâ€”the recipe for advanced <scp>NASH</scp>. Alimentary Pharmacology and Therapeutics, 2018, 47, 1220-1221.	1.9	6

#	Article	IF	Citations
127	Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4360-e4371.	1.8	6
128	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. Annals of Internal Medicine, 2017, 166, 230.	2.0	5
129	Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit. Hepatology, 2017, 66, 296-297.	3.6	5
130	Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis. Nutrition Research, 2021, 88, 34-43.	1.3	5
131	Are novel glucoseâ€lowering agents' cardiorenal benefits generalizable to individuals of <scp>Black</scp> race? A metaâ€trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. Diabetes, Obesity and Metabolism, 2022, 24, 154-159.	2.2	5
132	Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores. JMIR Medical Informatics, 2022, 10, e36997.	1.3	5
133	Insulin sensitizers in nonalcoholic steatohepatitis. Hepatology, 2011, 53, 1404-1405.	3.6	4
134	Healthcare Transition from Pediatric to Adult Medical Homes. Endocrine Practice, 2014, 20, 714-720.	1.1	4
135	Reply to â€œstatins and non-alcoholic steatohepatitisâ€• Metabolism: Clinical and Experimental, 2017, 66, e3-e5.	1.5	4
136	Re: â€œAssociation Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysisâ€•by Mantovani et al. (Thyroid 2018;28:1270â€“1284). Thyroid, 2019, 29, 452-452.	2.4	4
137	Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. Diabetes Care, 2022, 45, 1007-1012.	4.3	4
138	Basic Concepts in Insulin Resistance and Diabetes Treatment. , 2018, , 19-35.		3
139	Cytokeratin-18 and Enhanced Liver Fibrosis Scores in Type 1 and Type 2 Diabetes and Effects of Two Different Insulins. Journal of Investigative Medicine, 2018, 66, 661-668.	0.7	3
140	Response to Comment on Bril et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care 2018;41:187â€“192. Diabetes Care, 2018, 41, e137-e138.	4.3	2
141	Letter to the Editor: â€œHepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Contentâ€œ. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5249-5250.	1.8	2
142	Response to do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?. Liver International, 2015, 35, 2341-2342.	1.9	1
143	1461-P: Liver Fibrosis Is Common in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD). Diabetes, 2020, 69, 1461-P.	0.3	1
144	A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3076-e3077.	1.8	1

#	Article	IF	Citations
145	Diabetes medications improve cardiovascular outcomes. Current Opinion in Lipidology, 2016, 27, 633-635.	1.2	0
146	Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program. Clinical Pharmacology and Therapeutics, 2017, 101, 444-446.	2.3	0
147	Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344â€“1352. Diabetes Care, 2021, 44, e167-e167.	4.3	0
148	Plasma Branch Chain and Aromatic Amino Acid Levels are Associated with Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD). FASEB Journal, 2013, 27, .	0.2	0
149	Induction of Mitochondrial Triâ€carboxylic Acid Cycle is Sustained in Mice with Nonalcoholic Steatohepatitis (NASH). FASEB Journal, 2015, 29, 258.4.	0.2	0
150	Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes. Contemporary Diabetes, 2018, , 47-69.	0.0	0
151	MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors. Journal of the Endocrine Society, 2020, 4, .	0.1	0
152	Reply. Gastroenterology, 2022, , .	0.6	0
153	Response to: â€œNonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?â€• Obesity, 2022, , .	1.5	0
154	JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. Journal of Clinical Lipidology, 2022, 16, 115-127.	0.6	0